Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475968 | 1.00 | PIN1 (0.58) | PIN1IDO1KCNQ2CA1CA2 | |
| SCHEMBL176930 | 1.00 | PIN1 (0.58) | PIN1IDO1KCNQ2CA1CA2 | |
| SCHEMBL29528570 | 1.00 | PIN1 (0.58) | PIN1IDO1KCNQ2CA1CA2 | |
| SCHEMBL30252198 | 0.89 | IDO1 (0.50) | PIN1IDO1SIRT1CRBN | |
| SCHEMBL5732694 | 0.89 | IDO1 (0.50) | PIN1IDO1SIRT1CRBN | |
| SCHEMBL177082 | 0.89 | IDO1 (0.50) | PIN1IDO1SIRT1CRBN | |
| SCHEMBL29934643 | 0.89 | IDO1 (0.50) | PIN1IDO1SIRT1CRBN | |
| SCHEMBL3812210 | 0.89 | IDO1 (0.50) | PIN1IDO1SIRT1CRBN | |
| Pyridine SCHEMBL19209999 | 0.89 | PIN1 (0.49) | PIN1IDO1KCNQ2TRPM8 | |
| SCHEMBL5848583 | 0.87 | PIN1 (0.46) | PIN1IDO1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | claimed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | claimed |
| CN-115466209-A | Synthesis method of ropinirole cyclopentanoindolone impurity | 南通大学 | 2022-12-13 | — | — | CN | claimed |
| CN-108777958-B | Process for converting the S-enantiomer into its racemic form | FMC有限公司 | 2021-03-12 | — | — | CN | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| CN-106795115-A | Difluoromethyl nicotine indanyl formamide | 拜耳作物科学股份公司 | 2017-05-31 | — | — | CN | claimed |
| CN-104768934-A | Pyrazole indanyl carboxamides | BAYER CROPSCIENCE AG G | 2015-07-08 | — | — | CN | claimed |
| CN-103018349-B | Hydrindene amide compound detection analysis method | BEIJING MEDCONXIN PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-04-08 | — | — | CN | claimed |
| CN-104411689-A | Pyrazole indanyl carboxamides | BAYER CROPSCIENCE AG | 2015-03-11 | — | — | CN | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1294707-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-03-26 | — | — | EP | claimed |
| WO-2001098290-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| EP-1027350-A1 | AMINOMETHYL-BENZO A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021856-A1 | AMINOMETHYL-BENZO[A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 1999-05-06 | — | — | WO | claimed |
| US-4308380-A | 2-Lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | PIN1 3632/4885IDO1 625/4885KCNQ2 296/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | PIN1 3761/4885IDO1 3841/4885KCNQ2 1876/4885 |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | PIN1 950/4885IDO1 2208/4885KCNQ2 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.